|  |
| --- |
|  |

|  |  |  |  |
| --- | --- | --- | --- |
| **TOCCV1\_ver3.0 Interim Position Statement: Tocilizumab for patients admitted to ICU with COVID-19 pneumonia (adults)** | | | |
| **Patient NHS No:** |  | **Trust:** |  |
| **Patient Hospital No:** | \* | **Practice Code:** |  |
| **Patient's Initials and DoB:** |  | **GP Postcode:** |  |
| **Choose Consultant:** | |  |  | | --- | --- | |  | select |   help | | |
| **Consultant Name:** | \* | **Other Contact Details:** | \* |
| **Notification Email Address:**  (@NHS.net account ONLY) | | | |
| **Treatment Start Date:** | Clear selected value   \* | | |
|  | | | |

|  |  |
| --- | --- |
| **Please indicate whether patient meets the following criteria:** | **Please tick** |
| 1. I confirm that the patient is an adult with SARS-CoV-2 infection\*  \* In the absence of a confirmed virological diagnosis, tocilizumab should only be used when a multidisciplinary team have a high level of confidence that the clinical and radiological features suggest that COVID-19 is the most likely diagnosis. | |  | | --- | | Yes | | No |   \* Required |
| 2. I confirm intravenous tocilizumab has been prescribed as the patient is an adult who has been admitted to ICU with severe pneumonia requiring respiratory support\*\*, such as high-flow nasal oxygen, CPAP or non-invasive ventilation, or invasive mechanical ventilation and **all** of the following apply:  • No more than 24 hours has elapsed since ICU admission or more than 24 hours after starting respiratory support (whichever is the later)  • The patient will receive tocilizumab according to the Interim Position Statement: IL-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pneumonia (adults)\*\*\* and does not meet any of the exclusion criteria  • The patient will receive a maximum number of two doses  \*\* Or admitted to ICU with organ failure requiring support as infusion of vasopressor or inotropes or both  \*\*\* As part of the interim position statement hospitals are strongly encouraged to submit data through the ISARIC 4C Clinical Characterisation Protocol (CCP) case report forms (CRFs), as coordinated by the COVID-19 Clinical Information Network (CO-CIN)  **NB: For adult patients with SARS-CoV-2 infection who have not been admitted to ICU, sites should consider randomisation to the immunomodulator arm in the RECOVERY trial if this is available** | |  | | --- | | Yes | | No |   \* Required |